B Lynne Parshall Sells 5,000 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director B Lynne Parshall sold 5,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $76.27, for a total value of $381,350.00. Following the completion of the transaction, the director owned 51,344 shares in the company, valued at $3,916,006.88. This represents a 8.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

B Lynne Parshall also recently made the following trade(s):

• On Wednesday, February 11th, B Lynne Parshall sold 5,000 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $82.72, for a total value of $413,600.00.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ IONS opened at $75.71 on Friday. The firm has a market capitalization of $12.51 billion, a P/E ratio of -31.03 and a beta of 0.40. The company has a quick ratio of 3.81, a current ratio of 3.83 and a debt-to-equity ratio of 2.76. The stock’s 50-day simple moving average is $76.85 and its two-hundred day simple moving average is $77.00. Ionis Pharmaceuticals, Inc. has a twelve month low of $27.90 and a twelve month high of $86.74.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Wednesday, February 25th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.18). The business had revenue of $203.33 million during the quarter, compared to the consensus estimate of $156.07 million. Ionis Pharmaceuticals had a negative return on equity of 68.82% and a negative net margin of 40.36%.Ionis Pharmaceuticals’s revenue was down 10.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.66) earnings per share. As a group, equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Grandfield & Dodd LLC grew its position in Ionis Pharmaceuticals by 0.4% during the 4th quarter. Grandfield & Dodd LLC now owns 37,821 shares of the company’s stock worth $2,992,000 after acquiring an additional 146 shares during the last quarter. CWM LLC grew its position in Ionis Pharmaceuticals by 7.3% during the 3rd quarter. CWM LLC now owns 2,488 shares of the company’s stock worth $163,000 after acquiring an additional 170 shares during the last quarter. Wedmont Private Capital grew its position in Ionis Pharmaceuticals by 3.2% during the 4th quarter. Wedmont Private Capital now owns 5,536 shares of the company’s stock worth $460,000 after acquiring an additional 173 shares during the last quarter. Prospera Financial Services Inc grew its position in Ionis Pharmaceuticals by 3.9% during the 4th quarter. Prospera Financial Services Inc now owns 4,759 shares of the company’s stock worth $376,000 after acquiring an additional 178 shares during the last quarter. Finally, MetLife Investment Management LLC grew its position in Ionis Pharmaceuticals by 2.6% during the 4th quarter. MetLife Investment Management LLC now owns 9,674 shares of the company’s stock worth $765,000 after acquiring an additional 246 shares during the last quarter. 93.86% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on IONS shares. Morgan Stanley set a $95.00 target price on Ionis Pharmaceuticals and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Royal Bank Of Canada restated an “outperform” rating on shares of Ionis Pharmaceuticals in a research note on Wednesday, February 25th. Piper Sandler upped their target price on Ionis Pharmaceuticals from $87.00 to $100.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th. Needham & Company LLC increased their price objective on Ionis Pharmaceuticals from $103.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research report on Thursday, January 22nd. Seventeen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $94.37.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.